Blocking of the DNA damage repair pathway with an ATM inhibitor and the PARP inhibitor, olaparib, potentiates the cytotoxic effects of doxorubicin in osteosarcoma cells overexpressing SIRT6. Here, PARP1 is linked to osteosarcoma.